

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

UPDATE ON THE INVESTIGATION

Reference is made to the announcements of GenScript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 21 September 2020, 22 November 2020, and 9 February 2021 (the “**Announcements**”). Unless the context requires otherwise, terms used in this announcement shall have the same meanings as defined in the Announcements.

The Board wishes to report on an update in connection with the Investigation pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Each of Nanjing Jinsirui Biotechnology Co., Ltd.* (南京金斯瑞生物科技有限公司) and Jiangsu Jinsirui Biotechnology Co., Ltd.* (江蘇金斯瑞生物科技有限公司), being indirect wholly-owned subsidiaries of the Company, three (3) employees and one (1) former employee who were involved in certain import and export activities of the Group, and Dr. Zhang Fangliang, being the former chairman and former chief executive officer of the Company and the former chairman of the board of directors and former chief executive officer of Legend Biotech, have been informed by the Zhenjiang Customs Anti-Smuggling Branch, the People’s Republic of China (the “**PRC**”) (the “**Authority**”) that the Investigation has been completed, and their respective matter has been handed over to the Zhenjiang Municipal People’s Procuratorate (the “**Procuratorate**”) for examination and prosecution. As advised by the PRC legal advisors of the Company, this is an expected and ordinary procedural development under the PRC legal system, and it would take time for the Procuratorate to make a decision on whether to file any formal charge on any entity or individual.

As at the time of this announcement, to the best of the Company’s knowledge, no formal charges have been made or filed against any entity or individual.

To the best of the Company's knowledge, there have been no other details released by the Authority or the Procuratorate as at the date of this announcement.

As at the date of this announcement, the Group's business operations remain normal.

The Company has taken legal advice as appropriate. The Company will monitor this matter and will continue to proactively assist the law enforcement authority with the Investigation, if required. The Company will make public announcement in a timely manner on any important development of the Investigation.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 25 May 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*